Open an account

Immunome

IMNM · NASDAQ

$17.92+$1.15 (+6.86%)TodayMarket closed ·
Prev close $16.77

About IMNM

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Bothell, Washington and currently employs 117 full-time employees. The company went IPO on 2020-10-02. The firm is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The firm's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.

Employees
117
Headquarters
Bothell, Washington
Listed
Oct 2, 2020
Sector
Health Care
Industry
Biotechnology
Website
immunome.com

IMNM key statistics

Market cap
2.11B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.51M
Volume
2.03M
Open price
$16.74
High today
$18.27
Low today
$16.55
52 Week high
$30.06
52 Week low
$14.64

Immunome (IMNM) at a glance

Immunome (IMNM) last traded at $17.92, with a market cap of 2.11B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $16.55 and $18.27. The current price is 8.3% above the day's low and 1.9% below its high.

Volume so far is 2.03M shares, above the average of 1.51M shares a day.

Over the past year Immunome has ranged from $14.64 to $30.06, and now sits 21% of the way up that range.

Immunome met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.65 per share against an estimate of -$0.5326.

The average analyst price target is $35.63, 98.8% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

93%of 14 analyst ratings say Buy
  • Buy92.9%
  • Hold7.1%
  • Sell0.0%
Price target · 17 analystsAvg $35.63
Low
$24.24
Now
$17.92
High
$42.00

IMNM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 16.3% on average.

  1. Q3 FY24: reported -$0.78 per share against an estimate of -$0.5695
  2. Q4 FY24: reported -$1.28 per share against an estimate of -$0.5904
  3. Q1 FY25: reported -$0.52 per share against an estimate of -$0.6947
  4. Q2 FY25: reported -$0.50 per share against an estimate of -$0.5395
  5. Q3 FY25: reported -$0.65 per share against an estimate of -$0.5857
  6. Q4 FY25: reported -$0.76 per share against an estimate of -$0.614
  7. Q1 FY26: reported -$0.48 per share against an estimate of -$0.5736
  8. Q2 FY26: reported -$0.65 per share against an estimate of -$0.5326

IMNM news

  • Press releaseBusiness Wire

    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

  • Press releaseBusiness Wire

    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releaseBusiness Wire

    Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releaseBusiness Wire

    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

  • Vandana Singh

    Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review

Similar companies

Companies in the same industry as Immunome

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.